IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia

This study tests a new cell therapy called IL-5 CAR-T cells — immune cells that have been re-engineered to specifically attack a protein (IL-5 receptor) found on abnormal white blood cells — in patients with eosinophilic leukemia (a rare blood cancer involving abnormally elevated eosinophils) that has not responded to standard treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with eosinophilic leukemia per current diagnostic criteria - The IL-5 receptor (CD125) is expressed on at least 50% of your leukemic cells - Your disease has not responded to or relapsed after prior treatments **You may NOT be eligible if...** - You do not have sufficient expression of the target protein on your cancer cells - You have significant organ damage from leukemia or other causes - You have active serious infections or autoimmune conditions Talk to your doctor to see if this trial is right for you.